The Efficacy and Safety of Arginine Hydrochloride Combined With Trimetazidine Hydrochloride Tablets in the Treatment of Patients With Hepatocellular Carcinoma. A Multicenter, Open, Randomized, Prospective Study (TAHCC)

NCT03278444 Phase 3 UNKNOWN

The purpose of this study is to evaluate the efficacy and safety of arginine hydrochloride combined with trimetazidine hydrochloride tablets in the treatment of patients with hepatocellular carcinoma.

Details

Lead sponsor	The First Affiliated Hospital of Zhengzhou University
Phase	Phase 3
Status	UNKNOWN
Enrolment	300
Start date	2017-07-18
Completion	2021-07

Conditions

• HCC

Interventions

• Basic drugs therapy of HCC
• Arginine hydrochloride
• Trimetazidine hydrochloride

Primary outcomes

• Overall Survival — 36 months
  from start of treatment to death from any cause, or last known date of survival

Countries

China